The short version of pentapeptide fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-21 and is reviewed periodically as new material appears.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
Signal transduction begins when the peptide binds GHSR-1a on pituitary somatotrophs. The receptor couples to Gq/11 proteins, activating phospholipase C, which cleaves phosphatidylinositol bisphosphate into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and the resulting rise in cytosolic calcium drives growth hormone vesicle fusion. Concurrent Gs coupling and cyclic AMP elevation have also been reported, and the relative contribution of each arm to the overall secretory response is not fully settled.
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentapeptide | Growth hormone secretagogue family |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | Contains two non-natural residues |
| Molecular formula | C38H49N9O5 | Free base form |
| Molecular weight | 711.85 g/mol | Calculated from formula |
| Primary target | GHS-R1a ghrelin receptor | Agonist activity |
Verification of identity and purity relies on analytical methods used across peptide chemistry. Reverse-phase high-performance liquid chromatography separates components by hydrophobicity and provides a purity estimate. Mass spectrometry confirms molecular mass and helps detect modifications. Together these techniques give complementary information about whether a sample matches its expected structure. Results depend on method parameters and reference standards, so reported purity values are meaningful only when the analytical conditions are stated. Consistency between laboratories requires comparable protocols and well-characterized reference materials.
Peptides such as ipamorelin are subject to chemical and physical degradation. Hydrolysis of peptide bonds, oxidation of susceptible residues, and aggregation are common pathways that reduce purity over time. The rate of these processes depends on temperature, moisture, pH, and the number of freeze-thaw cycles a sample undergoes. Because the compound is typically handled as a lyophilized powder, controlling moisture during storage is a central concern. Degradation products can be detected with separation techniques that resolve the parent peptide from related impurities.
Lyophilized material is generally stored frozen and protected from light and moisture. Typical recommendations place dry powder at temperatures well below freezing, while reconstituted solutions are kept cold and used within a defined window. Repeated freezing and thawing should be avoided because it can promote aggregation and loss of material. The choice of solvent matters as well; compatibility with the intended diluent should be checked before preparation. These handling practices aim to preserve both the quantity and the integrity of the peptide.
Olanzapine/fluoxetine (trade name Symbyax, created by Eli Lilly and Company) is a fixed-dose combination medication containing olanzapine (Zyprexa), an atypical antipsychotic, and fluoxetine (Prozac), a selective serotonin reuptake inhibitor (SSRI). Olanzapine/fluoxetine is primarily used to treat the depressive episodes of bipolar I disorder as well as treatment-resistant depression.
Luspatercept, sold under the brand name Reblozyl, is a medication used for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
facilitative transporters (allow solutes to flow downhill with their electrochemical gradients) secondary active transporters (allow solutes to flow uphill against their electrochemical gradient by coupling to transport of a second solute that flows downhill with its gradient such that the overall free energy change is still favorable) The SLC series does not include members of transport protein families that have previously been classified by other widely accepted nomenclature systems including:
There are also the testimonies of Raymond Queneau (1903–1976), born in Le Havre, the city served as a framework for his novel Un rude hiver (A harsh winter) (1939). The plot of Une maison soufflée aux vents (A house blown to the winds) by Émile Danoën, winner of the Popular Novel Prize in 1951, and its sequel Idylle dans un quartier muré (Idyll in a walled neighbourhood) were located in Le Havre during the Second World War. Under the name Port de Brume Le Havre is the setting for three other novels by this author: Cerfs-volants (Kites), L'Aventure de Noël (The Adventure at Christmas), and La Queue à la pègre (Queue to the underworld). Michel Leiris wrote De la littérature considérée comme une tauromachie (Of literature considered like a bullfight) in December 1945. Diana Gabaldon set the second novel in her Outlander series, Dragonfly in Amber (1992), partly in Le Havre. Two mystery novels take place in Le Havre: Le Bilan Maletras (The Maletras Balance) by Georges Simenon and Le Crime de Rouletabille (Crime at the Roulette table) by Gaston Leroux. In Rouge Brésil (Red Brazil), winner of the Goncourt Prize in 2001, Jean-Christophe Rufin describes Le Havre in the 16th century as the port of departure of French expeditions to the New World: the hero Villegagnon leaves of the port to conquer new lands for the French crown which become Brazil. Martine–Marie Muller tells the saga of a clan of Stevedores from Le Havre in the 1950s to the 1970s in Quai des Amériques (Quay of the Americas).
Sources: en.wikipedia.org
=== Synergistic toxicity === It has been found that some three-fingered toxins from mamba venom interact synergistically with each other. The molecular mechanisms of these interactions remain unknown. It is not known either whether calciseptine has a synergistic effect with other venom compounds.
At least eighteen people were killed and at least 78 others were injured in a Russian missile attack on Chernihiv. Ukraine claimed responsibility for an attack at the Dzhankoi air base in Crimea, during which six explosions were reported. Russian milbloggers and Ukrainian sources said that ATACMS missiles or ballistic missiles were used, some of which deployed cluster munitions. A milbloggers claimed 30 people were killed and 80 others wounded. Ukraine said four missile launchers were 'critically damaged' in the attack. Subsequent satellite pictures showed the destruction of between three and five S-300 or S-400 systems and other areas marked with "scorch marks" that suggested equipment that had been damaged but removed. Ukrainian media reported that the HUR struck a radar system in the Russian republic of Mordovia and a factory producing bomber aircraft in Tatarstan using drones. The Canadian government announced that it would budget some 1.6 billion Canadian dollars ($1.16 billion) in military aid for Ukraine over the next five years.
Immunology/Serology uses the process of antigen-antibody interaction as a diagnostic tool. Compatibility of transplanted organs may also be determined with these methods. Immunohematology, or blood bank determines blood groups, and performs compatibility testing on donor blood and recipients. It also prepares blood components, derivatives, and products for transfusion. This area determines a patient's blood type and Rh status, checks for antibodies to common antigens found on red blood cells, and cross matches units that are negative for the antigen. Urinalysis tests urine for many analytes, including microscopically. If more precise quantification of urine chemicals is required, the specimen is processed in the clinical biochemistry lab. Histopathology processes solid tissue removed from the body (biopsies) for evaluation at the microscopic level. Cytopathology examines smears of cells from all over the body (such as from the cervix) for evidence of inflammation, cancer, and other conditions. Molecular diagnostics includes specialized tests involving DNA and RNA analysis. Cytogenetics involves using blood and other cells to produce a DNA karyotype. This can be helpful in cases of prenatal diagnosis (e.g. Down's syndrome) as well as in some cancers which can be identified by the presence of abnormal chromosomes. Surgical pathology examines organs, limbs, tumors, fetuses, and other tissues biopsied in surgery such as breast mastectomies.
Partial agonism and signaling bias describe distinct pharmacological properties: partial agonism refers to the maximum response produced relative to a reference full agonist, whereas signaling bias describes the relative preference for different intracellular signaling pathways activated by the same receptor. Activation of MOR primarily couples the receptor to inhibitory Gi/o proteins, resulting in inhibition of adenylyl cyclase, reduced intracellular cyclic AMP (cAMP), modulation of potassium and calcium channels, and decreased neuronal excitability and neurotransmitter release. β-Arrestin recruitment represents a partially distinct signaling and regulatory pathway involved in receptor desensitization, trafficking, and internalization. Consequently, a ligand may display partial efficacy for G-protein signaling while producing substantially weaker β-arrestin recruitment. MORs may also form receptor homomers containing more than one receptor protomer. Therefor occupancy of one protomer by a partial agonist does not necessarily prevent a second ligand from occupying the other orthosteric binding site of the second protomer. Thus, a 48%-efficacy partial agonist and a second partial agonist exhibiting 66% efficacy would occupy the second separate protomer within the same receptor complex. Buprenorphine was patented in 1965, FDA approved for medical use as an analgesic in 1981, and FDA approved for treating opioid use disorder in 2002. It is on the World Health Organization's List of Essential Medicines.
The ultimate clinical candidate, D2E7, was created and manufactured at BASF Bioresearch Corporation and taken through most of the drug development process by BASF Knoll, then further development, manufacturing and marketing by Abbott Laboratories, after Abbott acquired the pharmaceutical arm of BASF Knoll. Since 2008, adalimumab had been approved by the FDA for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, moderate to severe chronic psoriasis and juvenile idiopathic arthritis. Although only approved for ulcerative colitis from late 2012, by the FDA in the disease's management, it had been used for several years in cases that have not responded to conventional treatment at standard dosing for Crohn's disease. Adalimumab, sold under the brand name Humira, was approved for use in the United States in 2002. Adalimumab, sold under the brand names Humira and Trudexa, was approved for use in the European Union in September 2003.
Sources: en.wikipedia.org
It is a synthetic pentapeptide in the growth hormone secretagogue family. The chain contains five residues, two of which are non-natural amino acids.
It acts as an agonist at the growth hormone secretagogue receptor, also known as the ghrelin receptor. Binding at pituitary somatotroph cells promotes growth hormone release.
Early studies report weaker effects on cortisol, prolactin, and appetite than compounds such as GHRP-6. The size of that difference in humans is not firmly established.
Both molecules activate the same receptor, GHSR-1a, but they share little sequence identity. Ghrelin is a 28-amino-acid hormone carrying a distinctive acyl modification, whereas ipamorelin is a short synthetic peptide. The shared target explains overlapping endocrine effects, while the different structures account for differences in metabolic stability and receptor selectivity.